Long-term maintenance of cytochrome P450 activities by rat hepatocyte/3T3 cell co-cultures in heparinized human plasma

被引:22
作者
Washizu, J
Berthiaume, F
Mokuno, Y
Tompkins, RG
Toner, M
Yarmush, ML
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med,Surg Serv, Boston, MA 02114 USA
[2] Shriners Hosp Children, Boston, MA USA
来源
TISSUE ENGINEERING | 2001年 / 7卷 / 06期
关键词
D O I
10.1089/107632701753337654
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Little information on the effect of plasma on hepatocyte cytochrome P450 (CYP) activities is currently available. We characterized the effect of plasma on CYPs of hepatocyte-mesenchymal cell co-cultures, which exhibit stable liver specific functions and may be potentially useful for bioartificial liver design. Rat hepatocyte-mouse 3T3-J2 cell co-cultures were maintained for 6 days in medium, and then switched to heparinized human plasma containing 3-methylcholanthrene (3MC; 2 muM), phenobarbital (PB; 1 mM), or no inducer for up to 7 days. CYP activities were measured in situ based on the o-dealkylation of ethoxy(EROD), methoxy- (MROD), pentoxy- (PROD), or benzyloxy- (BROD) resorufin. Plasma alone increased PROD/BROD but not EROD/MROD. The endogenous inducer was in the high molecular weight fraction (>5 kD) of plasma and inhibited by >5 nM okadaic acid and >10 muM dibutyryl cyclic AMP, two inhibitors of PB-inducible CYPs. Furthermore, plasma increased CYP1A1 and CYP2B1/2 mRNA levels. In plasma, 3MC induced EROD/MROD to about 60% of the level induced in culture medium while PB induced PROD/BROD that were three- to 10-fold above levels induced in medium. CYP activities decreased between days 2 and 7 of plasma exposure, but were enhanced by plasma supplementation with amino acids, insulin, glucagon, and hydrocortisone.
引用
收藏
页码:691 / 703
页数:13
相关论文
共 47 条
[1]   MAINTENANCE AND INDUCTION IN COCULTURED RAT HEPATOCYTES OF COMPONENTS OF THE CYTOCHROME-P450-MEDIATED MONOOXYGENASE [J].
AKRAWI, M ;
ROGIERS, V ;
VANDENBERGHE, Y ;
PALMER, CNA ;
VERCRUYSSE, A ;
SHEPHARD, EA ;
PHILLIPS, IR .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (08) :1583-1591
[2]  
Alexander DL, 1998, J CELL SCI, V111, P3311
[3]   Liver assist systems: state of the art [J].
Arkadopoulos, N ;
Detry, O ;
Rozga, J ;
Demetriou, AA .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1998, 21 (12) :781-787
[4]   Characterization of human xenoreactive antibodies in liver failure patients exposed to pig hepatocytes after bioartificial liver treatment - An ex vivo model of pig to human xenotransplantation [J].
Baquerizo, A ;
Mhoyan, A ;
Kearns-Jonker, A ;
Arnaout, WS ;
Shackleton, C ;
Busuttil, RW ;
Demetriou, AA ;
Cramer, DV .
TRANSPLANTATION, 1999, 67 (01) :5-18
[5]  
BARTOLO LD, 2000, BIOTECHNOL PROGR, V16, P102
[6]   Xenobiotic metabolism by cultured primary porcine hepatocytes [J].
Behnia, K ;
Bhatia, S ;
Jastromb, N ;
Balis, U ;
Sullivan, S ;
Yarmush, M ;
Toner, M .
TISSUE ENGINEERING, 2000, 6 (05) :467-479
[7]   Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells [J].
Bhatia, SN ;
Balis, UJ ;
Yarmush, ML ;
Toner, M .
FASEB JOURNAL, 1999, 13 (14) :1883-1900
[8]  
BITTNER MA, 1976, MOL PHARMACOL, V12, P966
[9]   Consideration of potential immunological problems in the application of xenogenic hybrid liver support [J].
Bornemann, R ;
Smith, MD ;
Gerlach, JC .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1996, 19 (11) :655-663
[10]   CYTOCHROME-P450 SPECIFICITIES OF ALKOXYRESORUFIN O-DEALKYLATION IN HUMAN AND RAT-LIVER [J].
BURKE, MD ;
THOMPSON, S ;
WEAVER, RJ ;
WOLF, CR ;
MAYER, RT .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (05) :923-936